ClinicalTrials.gg

Program

icatibant

Also written as “Icatibant”, “Icatibant Injection (Icanticure®)” and “TAK-667”.

Its studies are mostly in Angioedemas, Hereditary · Angioedema · Osteoarthritis, led by 3 companies.

Furthest: phase 4, since Nov 26, 200411 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda90 open or runningphase 3since Nov 26, 2004Nov 26, 2004none ahead
Nang Kuang Pharmaceutical10 open or runningphase 4since Mar 12, 2025Mar 12, 2025none ahead
Sanofi10 open or runningphase 2since Mar 14, 2006Mar 14, 2006none ahead

Also a collaborator on its studies: jerini-ag and ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2004First study: phase 3 study in AngioedemaNew to TakedaTakeda · NCT00097695 · 84 enrolled · United States
  2. Mar 14, 2006Sanofi's first study: phase 2 study in Joint DiseasesNew to SanofiSanofi · NCT00303056 · 590 enrolled · United States, Austria, Czech Republic and more
  3. Jul 12, 2007Phase 3 study in Angioedemas, HereditaryTakeda · NCT00500656 · 85 enrolled · Italy
  4. Jun 2, 2009Phase 3 study in Angioedemas, HereditaryTakeda · NCT00912093 · 98 enrolled · United States, Australia, Canada and more
  5. Oct 16, 2009Phase 3 study in Angioedemas, HereditaryTakeda · NCT00997204 · 151 enrolled · Argentina, Austria, Denmark and more
  6. Jun 28, 2011Phase 3 study in Angioedemas, HereditaryTakeda · NCT01386658 · 32 enrolled · United States, Australia, Austria and more
  7. Jul 25, 2013Phase 3 study in Angiotensin Converting Enzyme Inhibitor Induced AngioedemaTakeda · NCT01919801 · 118 enrolled · United States, Canada, Israel and more
  8. Jan 13, 2014Phase 1 study in Angioedemas, HereditaryTakeda · NCT02045264 · 12 enrolled · United States
  9. Mar 20, 2019Phase 3 study in Angioedemas, HereditaryTakeda · NCT03888755 · 8 enrolled · Japan
  10. Nov 29, 2020Phase 3 study in Angioedemas, HereditaryTakeda · NCT04654351 · 2 enrolled · Japan
  11. Mar 12, 2025Nang Kuang Pharmaceutical's first study: phase 4 study in Angioedemas, HereditaryNew to Nang Kuang PharmaceuticalNang Kuang Pharmaceutical · NCT07290855 · 5 enrolled · Taiwan

TargetBeta

BDKRB2 →read by rule
“Bradykinin B2 receptor antagonist”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07290855Angioedemas, Hereditary · Taiwan4CompletedNang Kuang PharmaceuticalMay 27, 20255
NCT04654351Angioedemas, Hereditary · Japan3CompletedTakedaJul 27, 20212
NCT03888755Angioedemas, Hereditary · Japan3CompletedTakedaFeb 12, 20168
NCT02045264Angioedemas, Hereditary · United States1CompletedTakedaFeb 27, 201412
NCT01919801Angiotensin Converting Enzyme Inhibitor Induced Angioedema · United States, Canada, Israel and more3CompletedTakedaAug 22, 2015118
NCT01386658Angioedemas, Hereditary · United States, Australia, Austria and more3CompletedTakedaMar 12, 201832
NCT00997204Angioedemas, Hereditary · Argentina, Austria, Denmark and more3CompletedTakedaJun 22, 2011151
NCT00912093Angioedemas, Hereditary · United States, Australia, Canada and more3CompletedTakedaOct 1, 201098
NCT00500656Angioedemas, Hereditary · Italy3CompletedTakedaJul 25, 200685
NCT00303056Joint Diseases · United States, Austria, Czech Republic and more2CompletedSanofiJul 2007590
NCT00097695Angioedema · United States3CompletedTakedaJul 17, 200684

How it is read

Names in the registry

  • “Icatibant”, 6 entries
  • “Icatibant Injection (Icanticure®)”, 1 entry
  • “TAK-667”, 1 entry
  • “icatibant”, 1 entry
  • “Icatibant (30 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.